KKR closed its $5.89 billion acquisition of Integer Holdings on schedule, completing a strategic bet on medical device manufacturing as global private equity dealmaking contracted sharply in August. The transaction helped healthcare emerge as the dominant sector in monthly PE volume despite broader market headwinds.
Integer Holdings manufactures components for cardiac rhythm management devices, neuromodulation systems, and portable medical equipment. The company operates 16 facilities across the US, Europe, and Asia with approximately 5,800 employees. KKR acquired Integer from Genstar Capital and Cardinal Health at an enterprise valuation representing 13.2x trailing twelve-month EBITDA, a premium to comparable medtech platform deals that typically trade between 10-11x. The transaction had been announced in May and cleared regulatory review without material concessions.
The timing matters because global PE dealmaking fell 42% month-over-month in August, driven by valuation disagreements between sponsors and sellers in technology and industrials. Healthcare transactions represented 31% of August's total PE volume, the highest monthly concentration since March 2021 when pandemic-driven telehealth deals peaked. KKR's Integer acquisition alone accounted for nearly 19% of August's global healthcare PE volume. This sectoral concentration suggests two things allocators should note: first, that healthcare asset pricing held firm while other sectors saw bid-ask spreads widen materially, and second, that large-cap sponsors with committed capital are willing to deploy at scale when they identify defensive revenue streams.
Integer's revenue profile is instructive. The company generates 78% of sales from components sold to original equipment manufacturers under multi-year supply agreements, creating visible forward revenue that justifies debt leverage in a higher-rate environment. KKR financed the transaction with $3.1 billion in senior secured term loans at SOFR plus 375 basis points, roughly 125 basis points tighter than comparable medtech LBOs priced in Q2. The debt structure suggests credit markets remain open for healthcare platforms with contracted cash flows, even as tech-focused PE deals face financing headwinds. This is the pricing signal: credit underwriters are differentiating aggressively based on end-market exposure.
Operators should watch three near-term developments. First, KKR will likely pursue a carveout integration strategy, separating Integer's legacy Cardinal Health infrastructure within 90-120 days. Second, the firm has historically moved quickly on bolt-on acquisitions post-close, and the medtech component supply chain has 6-8 subscale competitors with overlapping manufacturing footprints. Expect consolidation moves by year-end. Third, Integer's European facilities give KKR exposure to the Medical Device Regulation compliance cycle, which requires reauthorization of legacy devices by 2028. Companies that navigate MDR early gain pricing power; watch for KKR to accelerate compliance spending in Q4 2025 to capture that margin opportunity.
The Integer deal closes KKR's third healthcare platform acquisition above $5 billion since 2022, following its $5.4 billion Envision Healthcare take-private and $6.3 billion acquisition of Cotiviti. The pattern is capital concentration in assets with regulatory moats and recurring revenue, deployed at premium multiples while smaller sponsors sit on dry powder waiting for valuation resets that may not arrive.